Combating Depression: A History and Analysis of FDA Regulation of Selective Serotonin Reuptake Inhibitors

DSpace/Manakin Repository

Combating Depression: A History and Analysis of FDA Regulation of Selective Serotonin Reuptake Inhibitors

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Wray, Katherine en_US
dc.date.accessioned 2012-06-07T04:18:18Z
dc.date.issued 2004 en_US
dc.identifier.citation Combating Depression: A History and Analysis of FDA Regulation of Selective Serotonin Reuptake Inhibitors (2004 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846785
dc.description.abstract This paper explores historical and current regulation by the Food and Drug Administration (FDA) of the most widely-used class of antidepressant drugs, selective serotonin reuptake inhibitors (SSRIs). To begin, I discuss the evolution of societal understanding of depression, and I highlight the pharmaceutical industry’s role in shaping the public perception of the condition. Next, I describe the major classes of antidepressants, focusing on SSRIs and their promise of relief for depressed individuals, as well as their economic benefits to their manufacturers. Then I explore and analyze several interesting challenges posed by SSRIs and other psychotropic medications for the new drug application (NDA) process. Subsequent sections chronicle and critique two noteworthy FDA advisory committee hearings on the potential connection between SSRIs and suicidal and other violent tendencies in patients who take the drugs. Throughout the paper, I attempt to show that the agency strives admirably to fulfill its regulatory mandates that only safe and effective drugs reach the American consumer, and that prescribers and patients are aware of known risks. FDA considers varied and passionate viewpoints on the subject of SSRIs, and although it cannot ever entirely satisfy all interested parties, the agency seems to have recently struck an appropriate balance between widespread access to these drugs and warnings about their potential harms. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject ssri en
dc.subject depression en
dc.title Combating Depression: A History and Analysis of FDA Regulation of Selective Serotonin Reuptake Inhibitors en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T04:18:18Z

Files in this item

Files Size Format View
Wray.pdf 287.3Kb PDF View/Open
Wray.rtf 260.4Kb RTF file View/Open
Wray.html 207.8Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters